Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease

Author(s): Melda Comert Ozkan, Fahri Sahin, Guray Saydam

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 16 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.

Keywords: Autoimmune disorders, biological therapy, immune thrombocytopenic purpura, rituximab.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 14 May, 2015
Page: [1956 - 1962]
Pages: 7
DOI: 10.2174/0929867322666150319102830
Price: $65

Article Metrics

PDF: 48
PRC: 1